KAPA kairospharma.com Final Profit

Corporate emblem and logo of kairospharma.com (KAPA)

Stable advance funding from partners enables Kairos Pharma Ltd (KAPA) to develop antibodies against resistant cancer. The company's bottom line clearly demonstrates daily margin dynamics, where the value -0.01 describes the current yield level. Success is supported by a cohesive team of scientists motivated by stock options and strict adherence to the cold chain during the transportation of innovative drugs to clinics.

KAPA (Kairos Pharma Inc) Net Profit history from 09/17/2024 to 10/31/2026

Analytical breakdowns and data insights for company kairospharma.com (KAPA)

- stock value and consensus price forecast:
Market Price Kairos Pharma|KAPA - Price Target Chart
- market capitalization data:
Market Value KAPA|KAPA - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Kairos Pharma|KAPA - Book Capitalization|Market Cap to Net Assets Ratio kairospharma.com|KAPA - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Kairos Pharma Ltd|KAPA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Kairos Pharma|KAPA - Company Aggregate Debts|Debts to Book Value KAPA|KAPA - Company Long-Term Debt|Company Short-Term Debts Kairos Pharma|Quick Ratio kairospharma.com
- net income and valuation multiples indicators:
KAPA - Net Profit
Fundamental valuation:KAPA Kairos Pharma Inc
Manufactured product of Kairos Pharma Limited

Kairos Pharma Ltd (KAPA) focuses on clinical trials of oncology drugs and is actively seeking a strategic partner to expand its pipeline. The company's daily calculation of income and expense balances allows for the real-time tracking of business efficiency outside of GAAP frameworks, where the steady growth of this indicator amid volatility confirms fundamental stability and the fair value of capital.

Main competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Company Net Income Accuray Incorporated (ARAY)|Net Profit sellaslifesciences.com (SLS)|Net Profit ACTU (Actuate Therapeutics)|Net Profit Citius Oncology Inc. CTOR|TuHURA - Net Profit|Net Financial Result Protara Tx TARA|Fate Therapeutics, Inc. (FATE) - Company Net Income|Aadi Bioscience - Final Profit|Company Net Income TScan Therapeutics Inc|Company Net Income Champions Oncology Corp CSBR|Company Net Income XBiotech Inc. (XBIT)|Net Financial Result cel-sci.com|OS Therapies Incorporated - Net Income|Final Profit RADX|ARTV - Company Net Income|Profit After Tax ANL|VERU: Net Profit|Tempest Therapeutics Corp - Final Profit|XLO (Xilio Therapeutics Inc) - Net Profit|Net Profit Enochian BioSciences|Company Net Income Mural Oncology plc (MURA)|OKUR (onkuretherapeutics.com) - Final Profit|Company Net Income CytoMed Therapeutics Limited GDTC|CRIS - Net Income|Apollomics Corp - Net Profit|THAR - Net Profit|ADVB (advanbiomed.com) - Net Income|Genprex Inc. - Final Profit|Company Net Income Calidi Biotherapeutics Inc.|Company Net Income SBFM|Net Income XBIO (Xenetic Biosciences)|Profit After Payment of Taxes SLRX|Net Profit PPBT (Purple Biotech Ltd.)|AONC: Company Profit|BGNE - Company Net Income|CKPT - Net Profit|ELEV: Net Profit|iCAD (ICAD) - Net Profit|Company Net Income Ikena Oncology Inc.|Notable Labs Ltd - Profit After Tax|Net Profit VIRX|Net Profit MorphoSys Corporation (MOR)|Net Profit NAYA (NAYA Biosciences)|AAPGV - Net Income